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In a Phase II RCT with multiple active treatments, we may
often wish to take forward a treatment to Phase III based
on multiple criteria and outcomes. In addition to efficacy,
factors such as cost and the adverse event rate may play a
key role in the decision making process. Using a Bayesian
analysis, all relevant criteria can be considered, and a uti-
lity function employed to obtain the optimal treatment.
An example is presented, detailing the results of an
RCT comparing Moxifloxacin, Doxycycline and Azithro-
mycin against placebo in the treatment of COPD, using
the criteria efficacy (reduction in airway bacterial
counts), adverse event profile, treatment adherence,
resistance to study drug and cost.
The relevant criteria of importance were chosen by the
trial investigators. For each chosen criterion, a Bayesian
analysis was performed and the effect estimates ranked,
with uncertainty in the effect sizes automatically propa-
gated to uncertainty in the ranks.
Each criterion was assigned a weight a priori, and
these weights determined the relative importance of
each criterion. The weights were chosen based on an
elicitation exercise conducted with the clinicians,
whereby possible outcomes were presented under var-
ious weighting scenarios in an iterative exercise until a
consensus was achieved.
Finally, a utility function combined the elicited weights
with the criteria ranks to provide an overall ranking for
each treatment. The treatment recommended for Phase
III was taken to be the one with the highest mean utility.
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